IMUX
HEALTHCAREImmunic Inc
$11.02-0.26 (-2.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMUX Today?
No stock-specific AI insight has been generated for IMUX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.06$15.10
$11.02
Fundamentals
Market Cap$150M
P/E Ratio—
EPS$-6.20
Dividend Yield—
Dividend / Share—
ROE-16.5%
Profit Margin—
Debt / Equity—
Trading
Volume462K
Avg Volume (10D)—
Shares Outstanding13.6M
IMUX News
20 articles- Immunic to Participate in Investor and Medical Conferences in MayYahoo Finance·Apr 30, 2026
- Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readoutProactive Investors·Apr 28, 2026
- Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical OfficerYahoo Finance·Apr 28, 2026
- Immunic to implement 1-for-10 reverse stock splitProactive Investors·Apr 23, 2026
- Immunic, Inc. Announces 1-for-10 Reverse Stock SplitYahoo Finance·Apr 23, 2026
- Immunic to Participate in Scientific and Medical Conferences in AprilYahoo Finance·Apr 9, 2026
- Immunic COO highlights the importance of science-led innovation to mark World Health DayYahoo Finance·Apr 7, 2026
- Immunic Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Apr 1, 2026
- Immunic appoints biopharmaceutical executive Jon Congleton to boardProactive Investors·Mar 31, 2026
- Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon CongletonYahoo Finance·Mar 31, 2026
- Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on MarketsMotley Fool·Mar 24, 2026
- Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus CalciumYahoo Finance·Mar 20, 2026
- Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA NextMarketbeat·Mar 20, 2026
- Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink ConferenceMarketbeat·Mar 18, 2026
- Immunic secures European patent for MS drug candidate vidofludimus calciumProactive Investors·Mar 10, 2026
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumYahoo Finance·Mar 10, 2026
- Immunic to present at healthcare investor conferences in MarchProactive Investors·Mar 3, 2026
- Immunic to Participate in Investor Conferences in MarchYahoo Finance·Mar 3, 2026
- Immunic secures $400M to support late-stage MS trials - ICYMIProactive Investors·Feb 28, 2026
- Immunic sets stage for phase 3 MS data readout after $400M financingProactive Investors·Feb 26, 2026
All 20 articles loaded
Price Data
Open$11.21
Previous Close$11.28
Day High$11.33
Day Low$10.41
52 Week High$15.10
52 Week Low$5.06
52-Week Range
$5.06$15.10
$11.02
Fundamentals
Market Cap$150M
P/E Ratio—
EPS$-6.20
Dividend Yield—
Dividend / Share—
ROE-16.5%
Profit Margin—
Debt / Equity—
Trading
Volume462K
Avg Volume (10D)—
Shares Outstanding13.6M
About Immunic Inc
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—